Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex® in patients with uveitic cystoid macular edema

被引:19
|
作者
Bansal, Pooja [1 ]
Agarwal, Aniruddha [2 ]
Gupta, Vishali [1 ]
Singh, Ramandeep [1 ]
Gupta, Amod [1 ]
机构
[1] Postgrad Inst Med Educ & Res, Adv Eye Ctr, Dept Ophthalmol, Chandigarh 160012, India
[2] Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, Omaha, NE USA
关键词
Cystoid macular edema; dexamethasone implant; external limiting membrane; optical coherence tomography; Ozurdex; serous retinal detachment; uveitis; FOVEAL PHOTORECEPTOR LAYER; INNER/OUTER SEGMENT JUNCTION; VISUAL-ACUITY; RESOLUTION; INTEGRITY; ASSOCIATION; THERAPY; IMPACT; EYES;
D O I
10.4103/0301-4738.159870
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To correlate the structural and functional changes following intravitreal injection of dexamethasone 0.7 mg (Ozurdex (R)) implant in patients with recalcitrant uveitic cystoid macular edema (CME). Materials and Methods: In a prospective, interventional, nonrandomized study, 30 eyes (27 patients) with uveitic CME received Ozurdex (R) implant and were followed-up for 24 weeks at periodic intervals to monitor structural alterations seen on spectral domain optical coherence tomography (SD-OCT). The outcome measures included change in central macular thickness (CMT) and best-corrected visual acuity (BCVA) as well as structural alterations seen on OCT such as change in the height of cystoid spaces (CSs) and sub-foveal serous retinal detachment (SSRD). The integrity of external limiting membrane and inner-outer segment junction was assessed at baseline and follow-up visits. Results: Mean age of the patients was 46.09 +/- 15.66 years. The mean CMT decreased by 96 mu m at 1-day, 231.64 mu m at 1-week, 254.21 mu m at 4 weeks and 249.14 mu m at 12 weeks (P < 0.001) compared with baseline. BCVA improved from a baseline mean of 0.62 LogMAR units to 0.49 on day 1 to 0.31 at 24 weeks (P < 0.001). A decrease in the mean height of CS, that is, 133.28 mu m from a baseline of 317.71 mu m was noted on the 1st day (P < 0.001). 4 eyes demonstrated the presence of CS at 4 weeks, 1 eye at 6 weeks and 3 eyes at 12 weeks. At baseline, 16 eyes (53.33%) demonstrated the presence of SSRD. Among these, 11 eyes showed resolution of SSRD on day 1. SSRD resolved in all patients at 4 weeks and was maintained up to 24 weeks. Conclusions: Ozurdex (R) implant improves the visual outcome of patients with recalcitrant uveitic CME. Reversibility of retinal changes may be possible following treatment with dexamethasone implant. Thus final visual outcome may be independent of pretreatment CMT, the height of CS or SSRD.
引用
收藏
页码:416 / 422
页数:7
相关论文
共 50 条
  • [41] Intravitreal Dexamethasone Implant in Patients with Persistent Diabetic Macular Edema
    Zucchiatti, Ilaria
    Lattanzio, Rosangela
    Querques, Giuseppe
    Querques, Lea
    Del Turco, Claudia
    Cascavilla, Maria Lucia
    Bandello, Francesco
    OPHTHALMOLOGICA, 2012, 228 (02) : 117 - 122
  • [42] Optical coherence tomography in the diagnosis and monitoring of cystoid macular edema in patients with retinitis pigmentosa
    Chung, Hyewon
    Hwang, Jong-Uk
    Kim, June-Gone
    Yoon, Young Hee
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (08): : 922 - 927
  • [43] Safety and Efficacy of Intravitreal Dexamethasone Implant for Refractory Uveitic Macular Edema in Adults and Children
    Ratra, Dhanashree
    Barh, Atanu
    Banerjee, Manideepa
    Ratra, Vineet
    Biswas, Jyotirmay
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2018, 26 (07) : 1034 - 1040
  • [44] Spectral domain optical coherence tomography documented rapid resolution of pseudophakic cystoid macular edema with topical difluprednate
    Chalam, K. V.
    Khetpal, Vijay
    Patel, Chirag J.
    CLINICAL OPHTHALMOLOGY, 2012, 6 : 155 - 158
  • [45] Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial
    Thorne, Jennifer E.
    Sugar, Elizabeth A.
    Holbrook, Janet T.
    Burke, Alyce E.
    Altaweel, Michael M.
    Vitale, Albert T.
    Acharya, Nisha R.
    Kempen, John H.
    Jabs, Douglas A.
    Jaffe, Glenn J.
    Bunn, Christina F.
    Greene, LaToya
    Grewal, Dilraj
    Grout, Sean
    Hughes, Michael
    Imperio, Ryan
    Kelly, Michael P.
    Lutman, Brian
    Perez, Paola
    Yeh, Steven
    Dobbs, Jannah
    Fernandes, Alcides
    Gibbs, Deborah
    Leef, Donna
    Mazur, Kelly
    O'Keefe, Ghazala
    Waldron, Rhonda
    Thorne, Jennifer E.
    Adeyemo, Olukemi
    Belz, Joseph
    Berkenstock, Meghan
    Boring, Jeff
    Burkholder, Bryn
    Cain, Dennis
    Crowell, Eric
    Distler, Russ
    Emmert, David
    Graul, Janis R.
    Herring, Charles Mark
    Hines, Pat
    Hornbeak, Dana
    Khan, Irfan
    McDonald, Jacquelyn
    Miller, Kelly
    Moore, Robert
    Nwankwo, Antonia
    Okeagu, Chinwenwa
    Reddy, Ashvini
    Reed, Terry L.
    Rhoton, Nicholas
    OPHTHALMOLOGY, 2019, 126 (02) : 283 - 295
  • [46] Pseudophakic cystoid macular edema and spectral-domain optical coherence tomography-detectable central macular thickness changes with perioperative prostaglandin analogs
    Walkden, Andrew
    Porter, Louise F.
    Morarji, Jiten
    Kelly, Simon P.
    Sioras, Evangelos
    JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2017, 43 (08) : 1027 - 1030
  • [47] Intravitreal dexamethasone implant for macular edema following uncomplicated phacoemulsification
    Furino, Claudio
    Boscia, Francesco
    Recchimurzo, Nicola
    Sborgia, Carlo
    Alessi, Giovanni
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2014, 24 (03) : 387 - 391
  • [48] Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant
    Castro-Navarro, Veronica
    Monferrer-Adsuara, Clara
    Navarro-Palop, Catalina
    Montero-Hernandez, Javier
    Cervera-Taulet, Enrique
    BMC OPHTHALMOLOGY, 2022, 22 (01)
  • [49] Macular edema in the era of spectral-domain optical coherence tomography
    Hunter, Allan
    Chin, Eric K.
    Telander, David G.
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 2085 - 2089
  • [50] Differentiation of Underlying Pathologies of Macular Edema Using Spectral Domain Optical Coherence Tomography (SD-OCT)
    Dysli, Muriel
    Ruckert, Rene
    Munk, Marion R.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2019, 27 (03) : 474 - 483